The Significance of Bone Marrow Plasma Cell Percentage and Immature Plasma Cells in the Prognosis of Newly Diagnosed Multiple Myeloma Patients.
10.19746/j.cnki.issn.1009-2137.2025.02.023
- Author:
Yuan-Yuan ZHANG
1
;
Qi-Ke ZHANG
2
;
Xiao-Fang WEI
2
;
You-Fan FENG
2
;
Yuan FU
2
;
Fei LIU
2
;
Qiao-Lin CHEN
2
;
Yang-Yang ZHAO
2
;
Xiu-Juan HUANG
2
;
Yang CHEN
2
Author Information
1. The First School of Clinical Medical, Gansu University Of Chinese Medicine, Lanzhou 730000, Gansu Province, China.
2. Department of Hematology, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
plasma cell percentage;
immature plasma cells;
survival analysis;
prognosis
- MeSH:
Humans;
Multiple Myeloma/pathology*;
Prognosis;
Plasma Cells/cytology*;
Retrospective Studies;
Male;
Female;
Middle Aged;
Aged;
Bone Marrow
- From:
Journal of Experimental Hematology
2025;33(2):469-474
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the significance of the plasma cell percentage and immature plasma cells in the prognosis of patients with multiple myeloma (MM).
METHODS:The clinical data of 126 newly diagnosed MM patients in Gansu Provincial Hospital from June 2017 to November 2022 were retrospectively analyzed. The enrolled patients were divided into a higher plasma cell percentage group (group A) and a lower plasma cell percentage group (group B) according to the median plasma cell percentage (33.5%). The clinicopathological data of the two groups were compared, and the effect of plasma cell percentage on the prognosis of MM patients was analyzed using survival curves. On this basis, group A and group B were divided into subgroups with immature plasma cells (A1 group, B1 group) and subgroups without immature plasma cells (A2 group, B2 group), respectively, then the survival curves were used to analyze the effect of immature plasma cells on the prognosis of MM patients.
RESULTS:Among the 126 patients with MM, the proportions of patients with ISS stage III, elevated β2-microglobulin(β2-MG) level, and immature plasma cells in Group A were significantly higher compared those in Group B ( P =0.015, P =0.028, P =0.010). The median overall survival(OS) and progression-free survival(PFS) of group A were 32 months and 10 months, respectively. The median OS of group B was not reached, and the median PFS was 32 months. The 3-year OS rates of patients in group A and group B were 46.7% and 62.2%, respectively ( P =0.021), and the 3-year PFS were 29.2% and 42.5%, respectively ( P =0.033). There were no significant differences in OS and PFS between group A1 and group A2, or between group B1 and group B2 ( P >0.05). Multivariate COX survival analysis showed that the plasma cell percentage ≥33.5%（HR=1.253, 95%CI : 0.580-2.889, P =0.018）, age ≥65 years (HR=2.206, 95%CI : 1.170-3.510, P =0.012), lactate dehydrogenase(LDH) ≥250 U/L (HR=1.180, 95%CI : 0.621-2.398, P =0.048) and β2-MG ≥3.5 mg/L (HR=1.507, 95%CI : 0.823-3.657, P =0.036) were independent risk factors affecting OS in MM patients.
CONCLUSION:MM patients with a higher plasma cell percentage (≥33.5%) at the initial diagnosis have a later disease stage, poorer OS and PFS, compared to the patients with a lower percentage(<33.5%) of plasma cells. The presence or absence of immature plasma cells has no significant impact on the survival of MM patients.
